Complement Therapeutic Development Services for MASPs Updated at Creative Biolabs

October 27 18:05 2020
With more than a decade of exploration and expansion, Creative Biolabs now optimizes the customized complement therapeutic development services on the lectin pathway targets, such as MASP-1 and MASP-2.

New York, USA – October 27, 2020 – The complement system is an essential component of innate immunity, participating in the pathogenesis of inflammatory diseases and in host defense. In the lectin complement pathway, mannose-binding lectin (MBL) and ficolins act as recognition molecules, and MBL-associated serine protease (MASP) is a key enzyme.

Taking advantage of the one-stop drug discovery platforms, Creative Biolabs has accumulated rich experience in complement therapeutic development services covering therapeutic antibody development, complement test services, soluble complement regulator development, complement component inhibitor development, serine protease inhibitor development and anaphylatoxin receptor antagonist development. Now, the customized services based on the lectin pathway targets of MSAP-1 and MSAP-2 are upgraded to facilitate related research on a wide range of diseases, including COVID-19.

• Complement Therapeutic Target MSAP-1

MASP-1 is involved in the lectin pathway of the complement system and is responsible for cleaving C4 and C2 into fragments to form a C3-convertase. There is evidence showing that MSAP-1 may play a key role in the pathogenesis of recurrent diseases, subacute myocardial infarction and acute ischemic stroke, and a team of skillful experts is fully capable of providing standard or customized complement therapeutic development services for these MASP-1related diseases.

• Complement Therapeutic Target MSAP-2

MASP-2 is responsible for the lectin pathway activation and can cleave complement components C4 and C2 into C4a, C4b, C2a, and C2b, which is critical to research on chemotherapy-induced neutropenia and septic shock. Creative Biolabs offers high-quality custom drug development services for MASP-2, including recombinant protein expression and purification, complement antibody development, aptamer screening, small molecules inhibitor screening.

“As we know, a MASP-2 inhibitor, Narsoplimab, has been used for the treatment of IgA nephropathy, atypical hemolytic uremic syndrome, and other related disorders. And research shows that this kind of MASP-2 antibody could also rapidly decrease the levels of inflammatory biomarkers, thus exhibiting a great therapeutic potential against COVID-19,” introduced by a senior scientist at Creative Biolabs.

Creative Biolabs offers a broad and integrated portfolio of laboratory and manufacturing services for complement therapeutic. Apart from the aforementioned services, a series of off-the-shelf complement therapeutic products, ranging from antibodies, recombinant proteins, peptides to array kits (including C5 ELISA kits, C3A ELISA kits, MASP1 ELISA kits, etc), are also available.

For more information, please visit https://www.creative-biolabs.com/complement-therapeutics.

About Creative Biolabs

With an unrelenting drive in the biotechnology research area, Creative Biolabs has organized professional Ph.D.-level research teams experting in the field of complement therapeutic development, to work closely with each other to provide services and products ranging from therapeutic antibodies, soluble complement regulators, complement component inhibitors, protease inhibitors to anaphylatoxin receptor antagonists.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.creative-biolabs.com/complement-therapeutics


Warning: count(): Parameter must be an array or an object that implements Countable in /home/indoreonlinejour/himachalpradeshnewspaper.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7